Takeda and IDT Biologika to Manufacture J&J’s COVID-19 Vaccine

News
Article

The companies will use capacity at IDT previously reserved for Takeda’s dengue vaccine candidate, TAK-003, to manufacture Janssen Pharmaceutical’s single-shot COVID-19 vaccine.

Takeda announced on March 15, 2021 that it has entered into a mutual agreement with IDT Biologika, a contract development and manufacturing organization, to use capacity at IDT previously reserved for Takeda’s dengue vaccine candidate, TAK-003, to manufacture the single-shot COVID-19 vaccine from Janssen Pharmaceutical, a Johnson & Johnson company.

Under the terms of the agreement, the space will be used for three months before being returned to Takeda to resume manufacturing of its dengue vaccine, Takeda said in a company press release.

“We are pleased to work with IDT to support Janssen’s efforts to make its COVID-19 vaccine available and accessible to as much of the world as possible,” said Rajeev Venkayya, president, Global Vaccine Business Unit at Takeda, in the press release. “We also recognize the massive unmet need for a dengue vaccine and will work closely with IDT to mitigate the impact on the supply of TAK-003.”

“I am grateful to our longstanding customer Takeda for their flexibility, allowing us to help provide much-needed COVID-19 vaccines to the world,” added Jürgen Betzing, IDT Biologika’s CEO. “It has become abundantly clear over the past months that the challenges posed by the pandemic can only be solved by cooperation and commitment. I believe this short-term arrangement between three industry organizations demonstrates our sector’s willingness and ability to contribute to creatively solving this crisis.”

Takeda previously announced partnerships with Moderna and Novavax to help provide access to COVID-19 vaccines in Japan, according to the press release. Currently, the company is responsible for the development and commercialization of more than 250 million doses of Novavax’s COVID-19 vaccine and the distribution of 50 million doses of Moderna’s messenger RNA COVID-19 vaccine.

Source: Takeda

Recent Videos
Miguel Forte from ISCT and Kiji Therapeutics talks about the potential impact of a changing European political landscape.
Miguel Forte from ISCT and Kiji Therapeutics provides his insights into the changing political landscape in the US as well as legislative and regulatory adjustments
Miguel Forte from ISCT and Kiji Therapeutics chats about expectations for 2025 and the future technology agenda for industry.
Sheryl Johnson from Orbia Fluor & Energy Materials chats about gender diversity, how women are helping to advance innovation, sustainability challenges, and progress in the field of inhaled drugs.
Mike Baird from Schlafender Hase gives his predictions for how AI and ML may find use in the industry moving forwards and provides some predictions about M&A and the changing US government administration.
Mike Baird from Schlafender Haser discusses industry trends from 2024 and those expected to have an impact in 2025 from the perspective of a software developer.
Preeya Beczek from Beczek.COM gives her thoughts on the areas to watch with the new US administration and how Europe might be finalizing preparations for previous legislative changes
Related Content